MicroRNA-200b downregulates oxidation resistance 1 (Oxr1) expression in the retina of type 1 diabetes model

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 3, 2013, Pages 1689-1697

  Murray, Anne R ^a,b   Chen, Qian ^a,b   Takahashi, Yusuke ^a,b   Zhou, Kevin K ^a,b   Park, Kyoungmin ^a,b   Ma, Jian xing ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 200B;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B WAVE; BIOINFORMATICS; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOWN REGULATION; ELECTRORETINOGRAPHY; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; MICROARRAY ANALYSIS; MOUSE; MUELLER CELL; NICK END LABELING; NONHUMAN; OXIDATION RESISTANCE 1 GENE; OXIDATIVE STRESS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; DOWN-REGULATION; MICE; MICE, INBRED C57BL; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDATIVE STRESS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, NEUROPEPTIDE; RETINA; RNA, MESSENGER; TRANSFECTION; TYROSINE;

EID: 84875469801     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10921     Document Type: Article

References (55)

1. Xu S. MicroRNA expression in the eyes and their significance in relation to functions. Prog Retin Eye Res. 2009;28:87-116.
2. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010;11:252-263.
3. Kolfschoten IG, Roggli E, Nesca V, Regazzi R. Role and therapeutic potential of microRNAs in diabetes. Diabetes Obes Metab. 2009;11:118-129.
4. van den Berg A, Mols J, Han J. RISC-target interaction: cleavage and translational suppression. Biochim Biophys Acta. 2008; 1779:668-677.
5. Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clin Chem. 2009;55:623-631.
6. Pandey AK, Agarwal P, Kaur K, Datta M. MicroRNAs in diabetes: tiny players in big disease. Cell Physiol Biochem. 2009;23:221-232.
7. Hezova R, Slaby O, Faltejskova P, et al. MicroRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell Immunol. 2010;260:70-74.
8. Ferland-McCollough D, Ozanne SE, Siddle K, Willis AE, Bushell M. The involvement of microRNAs in Type 2 diabetes. Biochem Soc Trans. 2010;38:1565-1570.
9. Centers for Disease Control and Prevention. General information and national estimates on diabetes in the United States. National Diabetes Fact Sheet. 2007. Available at: http://www. cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf.
10. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124-136.
11. Antonetti DA, Barber AJ, Bronson SK, et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes. 2006;55:2401-2411.
12. Kaneto H, Matsuoka TA, Katakami N, et al. Oxidative stress and the JNK pathway are involved in the development of type 1 and type 2 diabetes. Curr Mol Med. 2007;7:674-686.
13. Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. Exp Diabetes Res. 2007;2007:43603.
14. Al-Shabrawey M, Smith S. Prediction of diabetic retinopathy: role of oxidative stress and relevance of apoptotic biomarkers. EPMA Journal. 2010;1:56-72.
15. Yang Y, Hayden MR, Sowers S, Bagree SV, Sowers JR. Retinal redox stress and remodeling in cardiometabolic syndrome and diabetes. Oxid Med Cell Longev. 2010;3:392-403.
16. El-Remessy AB, Tang Y, Zhu G, et al. Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation. Mol Vis. 2008;14:2190-2203.
17. Lamb RE, Goldstein BJ. Modulating an oxidative-inflammatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function. Int J Clin Pract. 2008;62:1087-1095.
18. Fukai T, Ushio-Fukai M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal. 2011;15:1583-1606.
19. Lubos E, Loscalzo J, Handy DE. Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal. 2011;15:1957-1997.
20. Oliver PL, Finelli MJ, Edwards B, et al. Oxr1 is essential for protection against oxidative stress-induced neurodegeneration. PLoS Genet. 2011;7:e1002338.
21. Elliott NA, Volkert MR. Stress induction and mitochondrial localization of Oxr1 proteins in yeast and humans. Mol Cell Biol. 2004;24:3180-3187.
22. Durand M, Kolpak A, Farrell T, et al. The OXR domain defines a conserved family of eukaryotic oxidation resistance proteins. BMC Cell Biol. 2007;8:13.
23. Jaramillo-Gutierrez G, Molina-Cruz A, Kumar S, Barillas-Mury C. The Anopheles gambiae oxidation resistance 1 (OXR1) gene regulates expression of enzymes that detoxify reactive oxygen species. PLoS One. 2010;5:e11168.
24. Volkert MR, Elliott NA, Housman DE. Functional genomics reveals a family of eukaryotic oxidation protection genes. Proc Natl Acad Sci U S A. 2000;97:14530-14535.
25. Natoli R, Provis J, Valter K, Stone J. Expression and role of the early-response gene Oxr1 in the hyperoxia-challenged mouse retina. Invest Ophthalmol Vis Sci. 2008;49:4561-4567.
26. Chen Y, Hu Y, Zhou T, et al. Activation of the Wnt pathway plays a pathogenic role in diabetic retinopathy in humans and animal models. Am J Pathol. 2009;175:2676-2685.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) Method. Methods. 2001;25:402-408.
28. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101-1108.
29. Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen JA. Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res. 2007;35:W71-W74.
30. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA. org resource: targets and expression. Nucleic Acids Res. 2008;36:D149-D153.
31. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15-20.
32. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA. 2004; 10:1507-1517.
33. Zeng Y, Cullen BR. Sequence requirements for micro RNA processing and function in human cells. RNA. 2003;9:112-123.
34. Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res. 1996;62:155-169.
35. Limb GA, Salt TE, Munro PM, Moss SE, Khaw PT. In vitro characterization of a spontaneously immortalized human Muller cell line (MIO-M1). Invest Ophthalmol Vis Sci. 2002; 43:864-869.
36. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
37. Haan C, Behrmann I. A cost effective non-commercial ECLsolution for Western blot detections yielding strong signals and low background. J Immunol Methods. 2007;318:11-19.
38. Kozak M. An analysis of 50-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 1987;15:8125-8148.
39. Takahashi Y, Moiseyev G, Chen Y, Ma JX. Identification of conserved histidines and glutamic acid as key residues for isomerohydrolase activity of RPE65, an enzyme of the visual cycle in the retinal pigment epithelium. FEBS Lett. 2005;579: 5414-5418.
40. Takahashi Y, Moiseyev G, Chen Y, Ma JX. The roles of three palmitoylation sites of RPE65 in its membrane association and isomerohydrolase activity. Invest Ophthalmol Vis Sci. 2006;47: 5191-5196.
41. Barber AJ, Antonetti DA, Kern TS, et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci. 2005;46:2210-2218.
42. Smith SB, Duplantier J, Dun Y, et al. In vivo protection against retinal neurodegeneration by sigma receptor 1 ligand ({thorn})-pentazocine. Invest Ophthalmol Vis Sci. 2008;49:4154-4161.
43. Akimov NP, Renteria RC. Spatial frequency threshold and contrast sensitivity of an optomotor behavior are impaired in the Ins2Akita mouse model of diabetes. Behav Brain Res. 2012;226:601-605.
44. Chan YC, Khanna S, Roy S, Sen CK. miR-200b targets Ets-1 and is downregulated by hypoxia to induce angiogenic response of endothelial cells. J Biol Chem. 2011;286:2047-2056.
45. Magenta A, Cencioni C, Fasanaro P, et al. miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ. 2011;18:1628-1639.
46. McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes. 2011;60:1314-1323.
47. Kovacs B, Lumayag S, Cowan C, Xu S. MicroRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci. 2011;52:4402-4409.
48. Bolzan AD, Bianchi MS. Genotoxicity of streptozotocin. Mutat Res. 2002;512:121-134.
49. Freeman WM, Bixler GV, Brucklacher RM, et al. Transcriptomic comparison of the retina in two mouse models of diabetes. J Ocul Biol Dis Infor. 2009;2:202-213.
50. Bringmann A, Pannicke T, Grosche J, et al. Muller cells in the healthy and diseased retina. Prog Retin Eye Res. 2006;25:397-424.
51. Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol. 1996;122:393-403.
52. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41:3158-3164.
53. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145:574-584.
54. Vinores SA, Youssri AI, Luna JD, et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol. 1997;12:99-109.
55. Peter ME. Targeting of mRNAs by multiple miRNAs: the next step. Oncogene. 2010;29:2161-2164.